West Pharmaceutical Services, Inc. $WST Stock Position Lifted by Whittier Trust Co.

Key Points

• Whittier Trust Co. increased its holdings in West Pharmaceutical Services by 2.2% during the second quarter, owning 45,188 shares valued at approximately $9.89 million.
• Analysts have varying ratings for West Pharmaceutical Services, with two strong buy, seven buy, and four hold ratings, and a target price averaging $321.89.
• The company reported a $1.84 EPS for the last quarter, exceeding expectations, with revenue of $766.50 million representing a 9.2% year-over-year increase.

Whittier Trust Co. lifted its holdings in West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 2.2% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 45,188 shares of the medical instruments supplier's stock after purchasing an additional 984 shares during the quarter. Whittier Trust Co. owned 0.06% of West Pharmaceutical Services worth $9,887,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of WST. Zions Bancorporation National Association UT bought a new position in shares of West Pharmaceutical Services in the first quarter worth $25,000. Quarry LP bought a new position in shares of West Pharmaceutical Services in the first quarter worth $27,000. First Horizon Advisors Inc. grew its stake in shares of West Pharmaceutical Services by 85.0% in the first quarter. First Horizon Advisors Inc. now owns 185 shares of the medical instruments supplier's stock worth $41,000 after purchasing an additional 85 shares in the last quarter. Cromwell Holdings LLC grew its stake in shares of West Pharmaceutical Services by 587.5% in the second quarter. Cromwell Holdings LLC now owns 220 shares of the medical instruments supplier's stock worth $48,000 after purchasing an additional 188 shares in the last quarter. Finally, Brooklyn Investment Group grew its stake in shares of West Pharmaceutical Services by 83.3% in the first quarter. Brooklyn Investment Group now owns 275 shares of the medical instruments supplier's stock worth $61,000 after purchasing an additional 125 shares in the last quarter. Institutional investors own 93.90% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on WST shares. Rothschild & Co Redburn started coverage on West Pharmaceutical Services in a research note on Monday, September 15th. They set a "buy" rating and a $311.00 target price for the company. Rothschild Redb raised West Pharmaceutical Services to a "strong-buy" rating in a research note on Monday, September 15th. Zacks Research cut West Pharmaceutical Services from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 23rd. Redburn Partners set a $311.00 target price on West Pharmaceutical Services in a research note on Monday, September 15th. Finally, UBS Group raised their target price on West Pharmaceutical Services from $285.00 to $320.00 and gave the company a "buy" rating in a research note on Friday, July 25th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $321.89.

West Pharmaceutical Services Trading Up 1.8%

Shares of NYSE WST opened at $279.90 on Wednesday. West Pharmaceutical Services, Inc. has a 12 month low of $187.43 and a 12 month high of $352.33. The company has a market cap of $20.13 billion, a price-to-earnings ratio of 41.90, a P/E/G ratio of 4.82 and a beta of 1.07. The company has a quick ratio of 2.08, a current ratio of 2.78 and a debt-to-equity ratio of 0.07. The business has a fifty day simple moving average of $256.43 and a 200-day simple moving average of $232.35.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its earnings results on Thursday, July 24th. The medical instruments supplier reported $1.84 EPS for the quarter, beating the consensus estimate of $1.51 by $0.33. West Pharmaceutical Services had a return on equity of 18.43% and a net margin of 16.48%.The business had revenue of $766.50 million during the quarter, compared to the consensus estimate of $725.11 million. During the same period in the prior year, the business posted $1.52 earnings per share. West Pharmaceutical Services's revenue was up 9.2% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2025 guidance at 6.650-6.850 EPS. Sell-side analysts predict that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.